Manila Times Business
Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical
SAN DIEGO and TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose” or the "Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced the closing of the plan of arrangement (announced on November 19, 2025 and February 24, 2026) pursuant to which HS North America Ltd. (the "Purchaser”), a wholly owned s
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Regenx Announces Non-Brokered Financing for Gross Proceeds of $720,000
4h ago
Ready for What's Next: From Learning to Earning in the Age of AI
4h ago
Shane Lukas’ TEDx Talk Examines the Hidden Cost of Values Conflict and Its Impact on Stress and Decision-Making
5h ago
Pushpay Debuts a Rebuilt Groups Experience, Kicking Off Its Most Ambitious Platform Overhaul to Date
5h ago